- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05365997
Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer (BE-EPiC)
Study Overview
Detailed Description
Patients with advanced cancer have poor quality of life and life expectancy. Palliative care is a medical specialty focusing on providing relief from the symptoms and stress of serious illnesses such as cancer. While palliative care referrals often occur in the inpatient setting for acutely ill individuals, early outpatient specialty palliative care concurrent with cancer-directed treatment improves quality of life and survival, is an evidence-based practice, and is endorsed by national guidelines. Palliative care can be provided in the ambulatory, telemedicine, or home-based settings. However, nearly half of patients with advanced cancer do not receive palliative care prior to dying. Lack of standardized referral criteria and screening methods for palliative care contributes to underutilization. There is a high need for strategies to increase use of palliative care in oncology.
Clinicians underutilize palliative care, initiating referrals a median of 2 months before death. This status quo bias, which predisposes clinicians to continue current practice even if not the optimal option, may lead to delayed or missed palliative care referrals. Additionally, optimism bias, the cognitive bias that causes clinicians to believe that their own patients are at lesser risk of negative outcomes, may cause clinicians to underestimate a patient's mortality risk or symptom burden, thus delaying palliative care referral. Finally, overconfidence bias, the propensity to overestimate one's desired behaviors when it is not objectively reasonable, may lead clinicians to incorrectly believe they are initiating more palliative care referrals than their peers.
Overcoming suboptimal clinician decision-making biases are key to increasing palliative care referrals. Principles from behavioral economics can inform "nudges" that change how clinicians receive information and make choices such as palliative care referral. Default, opt-out nudges that make the optimal choice the path of least resistance can mitigate clinicians' status quo bias. Reframing clinicians' prognoses by providing data-driven life expectancy assessments may combat optimism bias.
Early palliative care intervention can improve quality of life for patients with advanced cancer. Outpatient palliative care is available at 98% of National Cancer Institute (NCI)-designated cancer centers and 63% of non-NCI centers. Early outpatient palliative care concurrent with cancer-directed treatment improves quality of life, reduces symptom burden, and decreases rates of aggressive end of life care. Nevertheless, only a minority of patients who qualify for palliative care receive it.
The primary objective of the study is to evaluate the impact of sending behavioral nudges to clinicians, as compared to usual practice, on completion of palliative care referrals among patients with advanced cancer. Our secondary objectives are to identify the impact of prompted palliative care referrals on quality of life, acute care utilization, and end-of-life utilization. This is a 2-arm pragmatic randomized trial among approximately 250 outpatients with advanced cancer to assess response to behavioral nudges to refer to palliative care. The setting will be outpatient oncology at the Ann B. Barshinger Cancer Institute at Lancaster General Health. Eligible clinicians will be randomized in clusters by overlapping clinical team (pod) to receive default electronic medical record-based prompts for palliative care referral among advanced cancer patients (Arm 1) vs no intervention/usual practice (Arm 2). These nudges have been shown to positively influence clinician behavior and are often used to drive value-based oncology care; however, they have never been studied in the context of palliative care referral. The primary outcome is completion of a palliative care referral within 12 weeks of enrollment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17601
- Ann B. Barshinger Cancer Institute at Lancaster General Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a functional telephone number
- Receive ongoing care from hematology/oncology services within the Ann B. Barshinger Cancer Institute (ABBCI) at Lancaster General Health.
Exclusion Criteria:
- Patients appearing for a new patient visit
- Patients who have previously received palliative care
- Patients who are enrolled in an ongoing clinical trial of a therapeutic agent
- Patients who receive primary oncologic care within another institution
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Clinicians will receive no further interventions beyond usual practice.
|
|
|
Experimental: Intervention
Clinicians receive a nudge consisting of an electronic health record in-basket message indicating a patient has a default pended order for palliative care.
|
For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient.
Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care.
For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment.
For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of Palliative Care Visit
Time Frame: Within 12 weeks of the Index Visit
|
Binary outcome (yes/no) measured at the patient level among eligible patients based on the date of documented palliative care encounter
|
Within 12 weeks of the Index Visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life
Time Frame: 0 weeks and 9 weeks after Index Visit
|
Measured by the Functional Assessment of Cancer Therapy - General (FACT-G) among patients who receive palliative care compared to matched controls
|
0 weeks and 9 weeks after Index Visit
|
|
Average Quality of Life
Time Frame: 9 weeks after Index Visit
|
Measured by the Functional Assessment of Cancer Therapy - General (FACT-G) among patients who receive palliative care compared to matched controls
|
9 weeks after Index Visit
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ravi Parikh, MD, MPP, Penn/ACC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- UPCC 29921
- 849498 (Other Identifier: UPenn IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Second Affiliated Hospital of Soochow UniversityNot yet recruitingCancer | Solid Cancer
-
New Mexico Cancer Research AllianceOhio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center...RecruitingCancer | Cancer RiskUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
UNICANCERRecruitingAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Urothelial Cancer | Advanced Non Small Cell Lung Cancer (NSCLC)France
Clinical Trials on Default Nudge
-
Massachusetts General HospitalNational Institute on Aging (NIA); Massachusetts Institute of Technology; National...Active, not recruitingDepressive Disorder | Hypertension | Obesity | Diabetes Mellitus | Anxiety Disorders | Gestational Diabetes | Hypertension in PregnancyUnited States
-
Northwestern UniversityNational Institute of Mental Health (NIMH); University of PennsylvaniaCompletedSuicideUnited States
-
Arizona State UniversityCompleted
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Abramson Cancer Center at Penn MedicineAstraZeneca; National Comprehensive Cancer NetworkActive, not recruiting
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Corporal Michael J. Crescenz VA Medical CenterCompletedIdiopathic Pulmonary Fibrosis | COPD | Congestive Heart Failure | Malignancy | Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy | Other Interstitial Lung Disease Without Curative Therapy | NYHA Class IV or NYHA Class III Plus 1 Hospitalization... and other conditionsUnited States
-
University of PennsylvaniaCompletedControl Condition | How Incentive Receive | How Incentive Holdout | How Incentive Ineligible | How and Why Incentive Receive | How and Why Incentive Holdout | How and Why Incentive IneligibleUnited States
-
University of WarwickCompletedChronic Disease | Hospital Outpatient ClinicsUnited Kingdom
-
Rio de Janeiro State UniversityUniversity of Copenhagen; Oswaldo Cruz Foundation; Universidade Federal do Rio...Withdrawn